EMD Serono, Inc.
Serono, Inc., located in Rockland, MA, is the US affiliate of Serono,
S.A., a global biotechnology leader, headquartered in Geneva, Switzerland. The Company has six recombinant products on the market, Gonal-FÆ (follitropin alfa for injection), LuverisÆ (lutropin alfa), OvidrelÆ/OvitrelleÆ (choriogonadotropin alfa for injection), RebifÆ (interferon beta-1a), SerostimÆ [somatropin (rDNA origin) for injection] and SaizenÆ [somatropin (rDNA origin) for injection]. (LuverisÆ is not approved in the USA). In addition to being the world leader in
reproductive health, Serono has strong market positions in neurology,
metabolism and growth. The Company's research programs are focused on growing these businesses and on establishing new therapeutic areas. Currently, there are twenty-one new molecules in development.
In 2001, Serono achieved worldwide revenues of US$1.38 billion, and a net income of US$317 million, making it the third largest biotech company in the world based on revenues. The Company operates in 45 countries, and its products are sold in over 100 countries. Bearer shares of Serono S.A., the holding company, are traded on the virt-x (SEO) and its American
Depositary Shares are traded on the New York Stock Exchange (SRA).